Elite in Lymphadenectomy

Francesco Raspagliesi

Milan, IT 
Clinical Trials:Currently Recruiting for 1 Trial
Elite in Lymphadenectomy
Milan, IT 
OverviewLocationsClinical Research

Overview

Francesco Raspagliesi practices in Milan, Italy. Mr. Raspagliesi is rated as an Elite expert by MediFind in Lymphadenectomy. His top areas of expertise are Endometrial Cancer, Cervical Cancer, Ovarian Cancer, Lymphadenectomy, and Hysterectomy.

His clinical research consists of co-authoring 417 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 13 articles in the study of Lymphadenectomy.

Gender
Male

Locations

Milan, Italy
Other Locations
Rome, Italy
Naples, Italy
Trento, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors
Enrollment Status: Recruiting
Publish Date: March 03, 2025
Intervention Type: Biological
Study Drug: Dostarlimab
Study Phase: Phase 1
A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer (RUBY)
A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer (RUBY)
Enrollment Status: Active_not_recruiting
Publish Date: September 03, 2025
Intervention Type: Drug, Biological
Study Drugs: Dostarlimab, Carboplatin, Paclitaxel, Niraparib
Study Phase: Phase 3
A Randomized, Double-Blind, Phase 3 Trial of Maintenance with Selinexor/ Placebo After Combination Chemotherapy for Patients with Advanced or Recurrent Endometrial Cancer
A Randomized, Double-Blind, Phase 3 Trial of Maintenance with Selinexor/ Placebo After Combination Chemotherapy for Patients with Advanced or Recurrent Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 20, 2025
Intervention Type: Drug
Study Phase: Phase 3
View 2 Less Clinical Trial

415 Total Publications

Leveraging Real-World Data From a Clinicogenomic Database Addresses the Treatment Gap in Patients With High-Grade Serous Ovarian Cancer.
Leveraging Real-World Data From a Clinicogenomic Database Addresses the Treatment Gap in Patients With High-Grade Serous Ovarian Cancer.
Journal: JCO precision oncology
Published: September 26, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Raspagliesi's expertise for a condition
ConditionClose
View All 9 Advanced Conditions
View All 24 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile